title: Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer.
abstract: OBJECTIVE
  Currently, it is standard practice to avoid ALND in patients with negative SLN, whereas this procedure is mandated for those with positive SLN. However, there has been some debate regarding the necessity of complete ALND in all patients with positive SLN. This review article discusses the issues related to eliminating the need for ALND in selected patients with positive nodes.
  
  
  METHODS
  A review of the English language medical literature was performed using the MEDLINE database and cross-referencing major articles on the subject, focusing on the last 10 years.
  
  
  RESULTS
  Currently, complete ALND is mandated in patients with SLN macrometastases as well as those with clinically positive nodes. It is not clear whether SLN biopsy is appropriate for axillary staging in patients with initially clinically positive nodes (N1) that become clinically node-negative (N0) after neoadjuvant chemotherapy. Although there is debate regarding whether ALND should be performed in patients with micrometastases in the SLN, it seems premature to abandon ALND in clinical practice. Moreover, it remains unclear whether it is appropriate to avoid complete ALND in patients with ITC-positive SLN alone.
  
  
  CONCLUSIONS
  In the absence of data from randomised trials, the long-term impact of SLN biopsy alone on axillary recurrence and survival rate in patients with SLN micrometastases as well as those with ITC-positive SLN remains uncertain. These important issues must be determined by careful analysis of the results of ongoing clinical trials.
authors.affiliation: Department of Breast Oncology, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa 920-8640, Japan. nogumasa@med.kanazawa-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Noguchi
mesh_terms: D000328:Adult; D000368:Aged; D001365:Axilla; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008197:Lymph Node Excision / Q000592:standards* / Q000639:trends; D008198:Lymph Nodes / Q000473:pathology* / Q000601:surgery; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology*; D009367:Neoplasm Staging; D018579:Patient Selection; D018570:Risk Assessment; D021701:Sentinel Lymph Node Biopsy / Q000592:standards* / Q000639:trends; D016019:Survival Analysis; D016896:Treatment Outcome